Oppenheimer Turns Bullish on Savara as Molgramostim Moves Closer to Approval
Savara gets FDA priority review for its drug, analyst raises target to $11, sees strong approval chances and upside.
NOTRELOAD AI
P&G Beats Q3 Sales and EPS Estimates as Beauty Strength Offsets Rising Cost Pressures
P&G sales up 7% to $21.2B, earnings rise, costs increase, but company keeps growth outlook and boosts dividends again.
TSMC Surges as Taiwan Eases Single-Stock Investment Limits
Taiwan eased fund limits, letting investors buy more TSMC, boosting its stock to a record high on AI-driven growth.
Oracle: Wedbush Says It’s the Next AI Infrastructure Winner
Oracle is seen as an AI cloud winner; Wedbush rates it “Outperform” with a $225 target, citing strong AI infrastructure and fast growth.
JPMorgan Gives Hims & Hers a $35 Bullish Rating – Full GLP-1 Lineup Just Got Even Stronger
JPMorgan backs Hims & Hers Health as a strong buy, boosted by GLP-1 drugs and big deals with Novo Nordisk and Eli Lilly.
Cannabis Stocks Drop After Early Surge on Limited US Marijuana Rescheduling Move
Cannabis stocks fell after hype faded: US reform helps medical marijuana only, not full market, so investors took profits.